UA94395C2 - Производное изоксазолина и способ его получения - Google Patents

Производное изоксазолина и способ его получения

Info

Publication number
UA94395C2
UA94395C2 UAA200709610A UAA200709610A UA94395C2 UA 94395 C2 UA94395 C2 UA 94395C2 UA A200709610 A UAA200709610 A UA A200709610A UA A200709610 A UAA200709610 A UA A200709610A UA 94395 C2 UA94395 C2 UA 94395C2
Authority
UA
Ukraine
Prior art keywords
preparation
isoxazoline derivative
isoxazoline
derivative
preparing
Prior art date
Application number
UAA200709610A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хьюн Ік Шин
Хьєонг Воок Чой
Тае Хо Хео
Кью Воонг Лі
Джа Хоон Лі
Кі Соок Парк
Original Assignee
Елджі Лайф Саєнсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елджі Лайф Саєнсез Лтд. filed Critical Елджі Лайф Саєнсез Лтд.
Publication of UA94395C2 publication Critical patent/UA94395C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Данное изобретение касается производного изоксазолина, содержащего фрагмент циклического гемикеталя карбоновой кислоты формулы (1) EMBED ISISServer , (1) где R1 представляет собой изохинолинил, хинолинил или нафтил, и R2 представляет собой метил, этил, пропил или бутил, для применения в качестве ингибитора каспазы, способа его получения и фармацевтической композиции, которая его содержит.
UAA200709610A 2005-02-26 2006-02-21 Производное изоксазолина и способ его получения UA94395C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050016203 2005-02-26

Publications (1)

Publication Number Publication Date
UA94395C2 true UA94395C2 (ru) 2011-05-10

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200709610A UA94395C2 (ru) 2005-02-26 2006-02-21 Производное изоксазолина и способ его получения

Country Status (29)

Country Link
US (1) US8044080B2 (ru)
EP (1) EP1851214B1 (ru)
JP (1) JP4961357B2 (ru)
KR (1) KR100774999B1 (ru)
CN (1) CN101128459B (ru)
AP (1) AP2374A (ru)
AR (1) AR055314A1 (ru)
AU (1) AU2006217293B2 (ru)
BR (1) BRPI0607330B1 (ru)
CA (1) CA2598347C (ru)
DK (1) DK1851214T3 (ru)
EA (1) EA013005B1 (ru)
ES (1) ES2394480T3 (ru)
HK (1) HK1111146A1 (ru)
IL (1) IL185226A0 (ru)
MA (1) MA29311B1 (ru)
MX (1) MX2007010338A (ru)
MY (1) MY149181A (ru)
NO (1) NO341347B1 (ru)
NZ (1) NZ560805A (ru)
PE (1) PE20061076A1 (ru)
PL (1) PL1851214T3 (ru)
PT (1) PT1851214E (ru)
SG (1) SG156689A1 (ru)
SI (1) SI1851214T1 (ru)
TW (1) TWI377205B (ru)
UA (1) UA94395C2 (ru)
WO (1) WO2006090997A1 (ru)
ZA (1) ZA200707202B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
AR072181A1 (es) * 2008-07-11 2010-08-11 Gilead Sciences Inc Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6118907B2 (ja) * 2012-09-28 2017-04-19 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 植物病害を防除するための窒素含有ヘテロ環式化合物
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
WO2018133870A1 (zh) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
KR102437095B1 (ko) * 2019-04-19 2022-08-26 주식회사 엘지화학 캐스파제 저해제의 프로드럭
CN113767097A (zh) * 2019-04-30 2021-12-07 株式会社Lg化学 半胱天冬酶抑制剂的前药
EP3970698A4 (en) * 2019-05-31 2022-08-31 LG Chem, Ltd. INJECTABLE COMPOSITION WITH PRODRUG OF CASPASE INHIBITORS AND METHOD OF MANUFACTURE THEREOF
US20220226306A1 (en) * 2019-05-31 2022-07-21 Lg Chem, Ltd. Composition for caspase inhibitor prodrug injection
JP2023537012A (ja) * 2020-08-05 2023-08-30 エルジー・ケム・リミテッド 変形性関節症の緩和又は治療するためのカスパーゼ阻害剤の使用
KR20220076371A (ko) 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
WO2023132606A1 (ko) * 2022-01-04 2023-07-13 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
WO2023140582A1 (ko) * 2022-01-24 2023-07-27 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제
KR20230126654A (ko) 2022-02-23 2023-08-30 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법
WO2023182877A1 (ko) 2022-03-24 2023-09-28 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
KR19990079267A (ko) 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
AU5762899A (en) 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor
CA2388564C (en) * 1999-09-17 2007-11-06 Lg Chem Investment Ltd. Caspase inhibitor
TWI256952B (en) * 2003-08-27 2006-06-21 Sk Corp Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제

Also Published As

Publication number Publication date
EA200701810A1 (ru) 2008-02-28
IL185226A0 (en) 2008-02-09
AP2374A (en) 2012-03-07
EP1851214B1 (en) 2012-09-05
BRPI0607330B1 (pt) 2021-08-03
US8044080B2 (en) 2011-10-25
HK1111146A1 (en) 2008-08-01
MA29311B1 (fr) 2008-03-03
WO2006090997A1 (en) 2006-08-31
EP1851214A4 (en) 2009-10-28
MX2007010338A (es) 2007-10-11
ZA200707202B (en) 2008-10-29
CN101128459B (zh) 2011-10-05
TWI377205B (en) 2012-11-21
PL1851214T3 (pl) 2013-03-29
NO341347B1 (no) 2017-10-16
EP1851214A1 (en) 2007-11-07
US20080262032A1 (en) 2008-10-23
JP4961357B2 (ja) 2012-06-27
JP2008531551A (ja) 2008-08-14
NO20074895L (no) 2007-11-26
KR100774999B1 (ko) 2007-11-09
AR055314A1 (es) 2007-08-15
KR20060094868A (ko) 2006-08-30
CN101128459A (zh) 2008-02-20
TW200640918A (en) 2006-12-01
CA2598347C (en) 2011-08-02
SG156689A1 (en) 2009-11-26
MY149181A (en) 2013-07-31
SI1851214T1 (sl) 2012-11-30
ES2394480T3 (es) 2013-02-01
AU2006217293A1 (en) 2006-08-31
CA2598347A1 (en) 2006-08-31
NZ560805A (en) 2010-12-24
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
PE20061076A1 (es) 2006-12-27
BRPI0607330A2 (pt) 2009-09-29
PT1851214E (pt) 2012-10-18
EA013005B1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
UA94395C2 (ru) Производное изоксазолина и способ его получения
TW200833326A (en) Chemical compounds 572
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
WO2005005389A3 (en) Malonamide derivatives
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
MXPA05010020A (es) Derivados de oxamida.
BRPI0411087A (pt) aperfeiçoamentos em ou relacionados a compostos orgánicos
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
MX2007007899A (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
GEP20125563B (en) 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
GEP20094744B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
GB2415377A (en) Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids and process for preparation thereof